Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

This study tests a drug called nelmastobart in combination with docetaxel (standard chemotherapy) for people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after previous treatments. **You may be eligible if...** - You have been confirmed to have stage IIIb, IIIc, or IV non-squamous non-small cell lung cancer (NSCLC) that has returned or worsened - Your tumor tests positive for a protein called BTN1A1 (TPS score ≥50) - You have previously received appropriate treatments based on your tumor's genetic makeup and PD-1/PD-L1 therapy - You have adequate physical functioning (ECOG performance status) **You may NOT be eligible if...** - Your tumor does not meet the BTN1A1 positivity threshold - You have not received required prior therapies - You have poor overall health or organ function Talk to your doctor to see if this trial is right for you.